Literature DB >> 8835752

Terbinafine-induced cholestatic liver disease.

G A Lazaros1, G V Papatheodoridis, J K Delladetsima, N C Tassopoulos.   

Abstract

Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported. We describe a case of prolonged terbinafine-induced cholestatic liver disease. Extrahepatic cholestasis, viral hepatitis and autoimmune liver disorders were excluded. The histological findings of marked cholestasis without evidence of extrahepatic biliary obstruction or acute hepatitis were compatible with the diagnosis of drug-induced liver disease. Biochemical parameters of liver cell damage returned to normal levels 6 months later.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835752     DOI: 10.1016/s0168-8278(96)80273-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.

Authors:  L A García Rodríguez; A Duque; J Castellsague; S Pérez-Gutthann; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Systematic review of severe acute liver injury caused by terbinafine.

Authors:  Jun Yan; Xiaolin Wang; Shengli Chen
Journal:  Int J Clin Pharm       Date:  2014-07-02

Review 3.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

4.  Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.

Authors:  A Mallat; E S Zafrani; J M Metreau; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.

Authors:  Kartik Kumar; Anna Gill; Rachelle Shafei; Janine L Wright
Journal:  BMJ Case Rep       Date:  2014-12-05

Review 6.  Terbinafine-induced hepatitis and pancytopenia.

Authors:  G Conjeevaram; V Vongthavaravat; R Sumner; R S Koff
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.